NCT03356366: SEP-MRI

MRI Study of the Mechanisms Underlying Irreversible Disability in Multiple Sclerosis

Active, enrolled NA Last updated 6 August 2024

What this trial tests

NA trial testing MRI 3T in Multiple Sclerosis in 70 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

2 October 2017

Primary endpoint
16 January 2023

31 December 2028

Quick facts

Lead sponsor	Assistance Publique Hopitaux De Marseille
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	70
Start date	2 October 2017
Primary completion	16 January 2023
Estimated completion	31 December 2028
Sites	1 location across France

Drugs / interventions tested

• MRI 3T
• MRI 1,5T
• MRI 7T

Conditions studied

• Multiple Sclerosis — all drugs for Multiple Sclerosis →

Sponsor

Assistance Publique Hopitaux De Marseille — full company profile →

Who can join

18 and older, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multiple sclerosis (MS) is the first non-traumatic cause of disability in young people, responsible for physical but also cognitive deficits. MS is an inflammatory demyelinating and degenerative disease of the central nervous system. Recently, MRI technics have demonstrated their sensibility to the different processes involved in MS. Particularly, MRI has evidenced that the pathological process of MS is not restricted to the macroscopic lesions of the white matter but also involves the normal appearing white and grey matter. In the normal appearing brain tissue, demyelination, neuronal suffering and neuronal loss have been evidenced. Moreover, MRI has demonstrated the existence of brain functional reorganization processes that may limit the clinical expression of pathological injuries. Despite these important findings, the pathological underpinnings of irreversible disability are largely unknown. The present project aims to depict the main determinants of physical but also cognitive disability in patients with MS. To do this, a longitudinal study including 70 patients with MS using different MRI markers known to be sensitive to the different pathological aspects of MS will be performed. The relationships between these markers and the progression of disability will be assessed. Identification of the main pathological underpinnings of irreversible disability of MS will provide the most relevant therapeutic targets.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.